Abstract
The ultimate aim of therapy or vaccine design against HIV is to eliminate ongoing virus replication or prevent HIV infection. The task at hand is daunting given the wide array of HIV variants circulating and the immense degree of variation found within the virus, especially in the envelope glycoprotein. HIV utilizes the CD4 receptor and a range of 7 transmembrane chemokine coreceptors for cell entry, specifically CCR5 and CXCR4. These receptors provide a number of targets for therapy design, however, the finding that multiple receptors allow for viral entry suggests that targeting one may cause the virus to swirch to using another receptor. The molecular interactions directing coreceptor usage are complex and can involve the same modifications associated with escape from the effect of neutralizing antibodies (NAbs), indicating that they are not unrelated and can in all likelihood impact on each other. Furthermore, a large array of other receptors, other than CD4, CCR5 and/or CXCR4 can interact with HIV with consequences for HIV tranmssion as well as disease progression.
Keywords: HIV, CD4, CCR5, CXCR4, HIV-1 (co)Receptors, Vaccine, glycoprotein, CD4 receptor, chemokine, neutralizing antibodies, human immunodeficiency virus type 1, gp120/41, Maraviroc, Selzentry, Celsentri, C-type lectins, M-tropic, RANTES, macrophage inflammatory protein, CXC-chemokine receptor LESTER, fusin, G-protein coupled receptors, R5X4, X4 phenotype, serine, threonine, phosphorylation, GPCR, CC-chemokines, MIP-1, hematopoiesis, cardiogenesis, MHC-class-I epitopes, N linked glycosylation, glycan shield, TNX-355, Hu5A8, hu-PBM-NOD-SCID mice
Current Pharmaceutical Design
Title: HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design
Volume: 16 Issue: 33
Author(s): Georgios Pollakis and William A Paxton
Affiliation:
Keywords: HIV, CD4, CCR5, CXCR4, HIV-1 (co)Receptors, Vaccine, glycoprotein, CD4 receptor, chemokine, neutralizing antibodies, human immunodeficiency virus type 1, gp120/41, Maraviroc, Selzentry, Celsentri, C-type lectins, M-tropic, RANTES, macrophage inflammatory protein, CXC-chemokine receptor LESTER, fusin, G-protein coupled receptors, R5X4, X4 phenotype, serine, threonine, phosphorylation, GPCR, CC-chemokines, MIP-1, hematopoiesis, cardiogenesis, MHC-class-I epitopes, N linked glycosylation, glycan shield, TNX-355, Hu5A8, hu-PBM-NOD-SCID mice
Abstract: The ultimate aim of therapy or vaccine design against HIV is to eliminate ongoing virus replication or prevent HIV infection. The task at hand is daunting given the wide array of HIV variants circulating and the immense degree of variation found within the virus, especially in the envelope glycoprotein. HIV utilizes the CD4 receptor and a range of 7 transmembrane chemokine coreceptors for cell entry, specifically CCR5 and CXCR4. These receptors provide a number of targets for therapy design, however, the finding that multiple receptors allow for viral entry suggests that targeting one may cause the virus to swirch to using another receptor. The molecular interactions directing coreceptor usage are complex and can involve the same modifications associated with escape from the effect of neutralizing antibodies (NAbs), indicating that they are not unrelated and can in all likelihood impact on each other. Furthermore, a large array of other receptors, other than CD4, CCR5 and/or CXCR4 can interact with HIV with consequences for HIV tranmssion as well as disease progression.
Export Options
About this article
Cite this article as:
Pollakis Georgios and A Paxton William, HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079146
DOI https://dx.doi.org/10.2174/138161210794079146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intramedullary Well-differentiated Osteosarcoma: Imaging and Pathologic
Findings in 17 Patients
Current Medical Imaging Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Antitumor Titanium Compounds
Mini-Reviews in Medicinal Chemistry Characterization and Immunological Evaluation of Low-Molecular- Weight Alginate Derivatives
Current Topics in Medicinal Chemistry Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Drug Coated Clay Nanoparticles for Delivery of Chemotherapeutics
Current Nanoscience An Insight into Nanomedicinal Approaches to Combat Viral Zoonoses
Current Topics in Medicinal Chemistry Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects
Current Medicinal Chemistry From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs
Current Pharmaceutical Design The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Nanocarrier based Antiretroviral Drug Delivery Approaches
Pharmaceutical Nanotechnology Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
Current Drug Therapy In Silico Design of Protein Kinase Inhibitors: Successes and Failures
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct
Current Cancer Therapy Reviews Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism